Last reviewed · How we verify
LY3154207
At a glance
| Generic name | LY3154207 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease (PHASE2)
- A Study to Evaluate LY3154207 on the Brain of Healthy Participants (PHASE1)
- A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) (PHASE2)
- A Drug Interaction Study of LY3154207 in Healthy Participants (PHASE1)
- Study of LY3154207 in Healthy Participants (PHASE1)
- A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease (PHASE1)
- A Study of LY3154207 on Sleep in Healthy Male Participants (PHASE1)
- A Study of LY3154207 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3154207 CI brief — competitive landscape report
- LY3154207 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI